Ruifu Chemical is the leading manufacturer of 3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 503615-03-0) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Apixaban intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | 3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one |
| Synonyms | 3-(4-Morpholinyl)-1-(4-Nitrophenyl)-5,6-Dihydro-2(1H)-Pyridinone; 5,6-Dihydro-3-(4-Morpholinyl)-1-(4-Nitrophenyl)-2(1H)-Pyridinone; Apixaban Intermediate 3; Apixaban Impurity 36; Apixaban Process Impurity 1 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 503615-03-0 |
| Molecular Formula | C15H17N3O4 |
| Molecular Weight | 303.31 g/mol |
| Melting Point | 165.0~170.0℃ |
| Boiling Point | 506.5±50.0℃ |
| Density | 1.357g/mL |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Apixaban (CAS: 503612-47-3) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | Yellow Powder | Yellow Powder |
| Melting Point | 165.0~170.0℃ | 167.0~170.0℃ |
| Loss on Drying | ≤0.50% | 0.3% |
| Individual Impurity (Max.) | ≤0.50% | 0.3% |
| Total Impurities | ≤1.00% | 0.6% |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.4% |
| 1 H NMR Spectrum | Consistent with Structure | Complies |
| LC/MS | Consistent with Structure | Complies |
| Conclusion | The product has been tested & complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
3-Morpholino-1-(4-Nitrophenyl)-5,6-Dihydropyridin-2(1H)-one (CAS: 503615-03-0) is the intermediate for the synthesis of Apixaban (CAS: 503612-47-3).
Apixaban is a new type of oral Xa factor inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. The trade name is Eratol, which is a new type of oral anticoagulant. By inhibiting an important coagulation factor Xa, Apixaban can prevent thrombin production and thrombosis.
On April 26, 2007, Bristol-Myers Squibb joined hands with Pfizer to announce the cooperation in the development of a new oral anticoagulant Apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin. According to the cooperation agreement, Pfizer will pay an advance payment of US $0.25 billion to Bristol-Myers Squibb to bear the 60% of the total development cost of the anticoagulant Apixaban (to be implemented from January 1, 2007), while Bristol-Myers Squibb will bear the remaining 40%, thus obtaining the right to jointly develop and sell the drug.
In May 2011, Apixaban was the first to approve the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. Subsequently, the Canadian Food and Drug Administration, Japan, and the US FDA approved Ererto (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, the new anticoagulant drug Eloto (ELIQUIS)(apixaban) jointly developed by Bristol-Myers Squibb and Pfizer was officially announced to be listed in China. Ererto is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. Its listing provides a safe and effective new choice for clinical anticoagulation after orthopedic surgery, and brings good news to Chinese patients undergoing hip/knee elective replacement. Clinical studies have confirmed that compared with 40mg enoxaparin once a day, 2 times a day oral administration of Eratol (Apixaban) 2.5mg is more effective for preventing venous thromboembolism after hip or knee replacement surgery, and does not increase the risk of bleeding.
